Therapeutic role of low-dose mifepristone in the management of uterine fibroids: clinical outcomes and contemporary perspective
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20261157Keywords:
Mifepristone, Uterine fibroids, Low-dose therapy, Amenorrhea, Conservative managementAbstract
Background: Uterine fibroids are the most common benign tumors of the female reproductive tract and are a major cause of menstrual disturbances and anemia. Conservative medical therapies are increasingly preferred over surgical options in women desiring uterine preservation. Mifepristone, a progesterone receptor antagonist, has shown promising results in reducing fibroid volume and associated symptoms. Objectives were to evaluate the clinical efficacy and safety of low-dose mifepristone (25 mg daily) in reducing fibroid size and improving clinical symptoms among perimenopausal women with symptomatic leiomyomas.
Methods: This prospective observational study was conducted from June 2024 to July 2025 at the Department of Gynecology, Government Peripheral Hospital, Tondiarpet, Chennai. Ninety-three perimenopausal women aged 35-50 years with ultrasonographically confirmed symptomatic fibroids were treated with 25 mg mifepristone daily for three months. Clinical parameters, uterine and fibroid volumes, hemoglobin, and endometrial thickness were evaluated before and after therapy.
Results: Amenorrhea was achieved in 92.7% of patients. Mean uterine and myoma volumes decreased to 63.7% and 53.6% of baseline, respectively. Mean hemoglobin levels increased by 2.8 g/dl (37%) post-treatment. Endometrial thickening was mild in most patients, with two cases of simple hyperplasia without atypia. Headache was the most frequent adverse effect (12%), with no major hepatic or renal complications reported. Hysterectomy was avoided in 87.8% of patients.
Conclusions: Low-dose mifepristone (25 mg daily) is a safe, effective, and affordable therapeutic option for managing symptomatic uterine fibroids in perimenopausal women. It significantly reduces fibroid and uterine volume, controls bleeding, and improves hemoglobin levels, minimizing the need for surgical intervention.
References
Adamson GD. Treatment of uterine fibroids current findings with gonadotrophin releasing hormone agonists. Am J Obstet Gynecol. 1992;166:746-51.
Sankaran S, Manyonda IT. Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol. 2008;22(4):655-76.
Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007;87(4):725-36.
Wise L, Laughlin-Tommaso S. Epidemiology of Uterine Fibroids: From Menarche to Menopause. Clin Obstet Gynecol. 2016;59(1):2-24.
Marshall LM, Spiegelman D, Goldman MB. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70(3):432‐9.
Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone Is Essential for Maintenance and Growth of Uterine Leiomyoma. Endocrinology. 2010;151:2433-42.
Ono M, Yin P, Navarro A, Moravek MB, Coon JS, Druschitz SA, et al. Paracrine activation of WNT/beta-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci USA. 2013;110:17053-8.
Vannuccini S, Petraglia F, Carmona F, Calaf J. The modern management of uterine fibroids-related abnormal uterine bleeding. Fertil Steril. 2024;122(1):20-30.
Al Hilli MM, Stewart EA. Magnetic resonance-guided focused ultrasound surgery. Semi Reproduct Med. 2010;28(3):242-9.
Ng W, Jerath A, Wąsowicz M. Tranexamic acid: a clinical review. Anaesthesiol Intensive Ther. 2015;47(4):339‐50.
Sangkomkamhang US, Lumbiganon P, Pattanittum P. Progestogens or progestogen‐releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy). Cochrane Database Syst Rev. 2020;11(11):CD008994.
Bradley LD, Gueye NA. The medical management of abnormal uterine bleeding in reproductive‐aged women. Am J Obstet Gynecol. 2016;214(1):31‐44.
Ascoli M, Puett D. The gonadotropin hormones and their receptors. In: Strauss JF, Barbieri RL, eds. Yen and Jaffe's Reproductive Endocrinology: Expert Consult-Online and Print. 9th ed. Elsevier Inc. 2023;35‐55.
Sohn GS, Cho S, Kim YM. Working Group of Society of Uterine Leiomyoma. Current medical treatment of uterine fibroids. Obstet Gynecol Sci. 2018;61(2):192-201.
Kakade AS, Kulkarni YS. Mifepristone: current knowledge and emerging prospects. J Indian Med Assoc. 2014;112:36-40.
Chen L, Jia L, Li H, Yuan Y, Wang S, Tian L, et al. Effect of mifepristone on uterine fibroids: A systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 2025;54(5):102929.
Seth S, Goel N, Singh E, Mathur AS, Gupta G, Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman J Midlife Health. 2013;4(1):22-6.
Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: A randomized clinical trial. Fertil. Steril. 2020;114:44-55.
Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol. 2012;19:594-601.
Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve month safety and efficacy of low dose mifepristone for uterine myomas. J Minim Invasive Gynecol. 2005;12:227-33.
Chung YJ, Chae B, Kwak SH. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro. Int J Med Sci. 2014;11:276-81.
Murji A, Whitaker L, Chow TL, Sobel ML. Selective progesterone receptor modulators (SPRMs) for uterine fibroids Cochrane Database Syst Rev. 2017;4(4):CD010770.
Downloads
Published
How to Cite
Issue
Section
